{"name":"SkyePharma AG","slug":"skyepharma-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"SKP FlutiForm HFA pMDI","genericName":"SKP FlutiForm HFA pMDI","slug":"skp-flutiform-hfa-pmdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Flovent Fluticasone HFA","genericName":"Flovent Fluticasone HFA","slug":"flovent-fluticasone-hfa","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"FlutiForm 250/10","genericName":"FlutiForm 250/10","slug":"flutiform-250-10","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Fluticasone propionate 100","genericName":"Fluticasone propionate 100","slug":"fluticasone-propionate-100","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Fluticasone propionate 250","genericName":"Fluticasone propionate 250","slug":"fluticasone-propionate-250","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Fluticasone propionate/formoterol fumarate","genericName":"Fluticasone propionate/formoterol fumarate","slug":"fluticasone-propionate-formoterol-fumarate","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Formoterol fumarate 10","genericName":"Formoterol fumarate 10","slug":"formoterol-fumarate-10","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"SKP-Fluticasone","genericName":"SKP-Fluticasone","slug":"skp-fluticasone","indication":"Asthma (likely maintenance therapy)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Oral Prednisone 10mg","genericName":"Oral Prednisone 10mg","slug":"oral-prednisone-10mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SKP FlutiForm HFA pMDI","genericName":"SKP FlutiForm HFA pMDI","slug":"skp-flutiform-hfa-pmdi","phase":"phase_3","mechanism":"SKP FlutiForm HFA is a combination inhaled corticosteroid (fluticasone propionate) and long-acting beta-2 agonist (formoterol) delivered via pressurized metered-dose inhaler for maintenance treatment of asthma.","indications":["Asthma maintenance therapy"],"catalyst":""},{"name":"Flovent Fluticasone HFA","genericName":"Flovent Fluticasone HFA","slug":"flovent-fluticasone-hfa","phase":"phase_3","mechanism":"Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"FlutiForm 250/10","genericName":"FlutiForm 250/10","slug":"flutiform-250-10","phase":"phase_3","mechanism":"FlutiForm combines fluticasone propionate (an inhaled corticosteroid) with formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Fluticasone propionate 100","genericName":"Fluticasone propionate 100","slug":"fluticasone-propionate-100","phase":"phase_3","mechanism":"Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Fluticasone propionate 250","genericName":"Fluticasone propionate 250","slug":"fluticasone-propionate-250","phase":"phase_3","mechanism":"Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Fluticasone propionate/formoterol fumarate","genericName":"Fluticasone propionate/formoterol fumarate","slug":"fluticasone-propionate-formoterol-fumarate","phase":"phase_3","mechanism":"Fluticasone propionate/formoterol fumarate combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Formoterol fumarate 10","genericName":"Formoterol fumarate 10","slug":"formoterol-fumarate-10","phase":"phase_3","mechanism":"Formoterol fumarate is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Oral Prednisone 10mg","genericName":"Oral Prednisone 10mg","slug":"oral-prednisone-10mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SKP-Fluticasone","genericName":"SKP-Fluticasone","slug":"skp-fluticasone","phase":"phase_3","mechanism":"SKP-Fluticasone is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune and inflammatory responses.","indications":["Asthma (likely maintenance therapy)","Chronic obstructive pulmonary disease (COPD) (likely)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPTklpWk0tdlhwWmZNcWFsMk52WENKS2RyYldVSEpsWEp5VEVsTkVKUzViZXRwQzk1RWtXZDduOV9VNlhmeGJtb3ZEWHdBVUxsLUtYdHRyS1d5Qlc2M1Bzemg3ZGFWN1c4eC11Q3Vjcm1DbmhHanVwbFdZdTlQaXZocVBuZF8tMlVmYmhuVXYyZ2tKOUg4c0FVM3NkMUk0M2VrMUNOTlNyR3FlNnVj?oc=5","date":"2016-03-16","type":"deal","source":"BioSpace","summary":"UK’s Vectura Buys Skyepharma for $620 Million to Create Powerful Respiratory Company - BioSpace","headline":"UK’s Vectura Buys Skyepharma for $620 Million to Create Powerful Respiratory Company","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":8,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}